ArticleThe Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology2026
Clinical Impact of Cytomegalovirus Infection in Patients with Inflammatory Bowel Disease.
Article in The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsPatients with inflammatory bowel disease (IBD) are at increased risk of cytomegalovirus (CMV) infection, likely due to malnutrition and immunosuppressive therapies. Cytomegalovirus infection may contribute to worse disease outcomes, including higher colectomy rates. However, the prognostic value of serum cytomegalovirus deoxyribonucleic acid (CMV-DNA) levels and the clini cal significance of CMV colitis remain unclear. This study aimed to assess the impact of CMV infection on the clinical course of IBD. MATERIALS AND
methodsRetrospective analysis was performed on 141 hospitalized IBD patients with detectable serum CMV-DNA (>42 copies/mL). Cytomegalovirus colitis was diagnosed by histopathology or immunohistochemistry. Clinical features were compared between CMV colitis and non-colitis groups. Receiver operating characteristic analysis assessed the optimal CMV-DNA cut-off, and logistic regression identified predictors of adverse outcomes (mortality or colectomy).
resultsCytomegalovirus colitis was identified in 18.4% of patients. While there were no significant differences in age, treatment his tory, or colectomy rates between groups, patients with CMV colitis had significantly higher serum CMV-DNA levels (median: 837 vs. 267 copies/mL; P = .019), longer hospitalization durations (P = .001), and more frequent comorbidities (P = .019). The optimal CMV-DNA cut off was 468.5 copies/mL (area under the curve (AUC) 0.64; sensitivity 61.5%, specificity 61.7%). Adverse outcomes occurred in 24% of cases. Extensive colitis (odds ratio 2.92; P = .034) independently predicted poor outcomes; CMV-DNA levels did not.
conclusionCytomegalovirus colitis is an uncommon but clinically significant complication in IBD flares. Although high serum CMV DNA levels were associated with CMV colitis, their diagnostic value was limited. Extensive colitis is an independent predictor of poor outcomes. Cite this article as: Dursun B, Gumussoy M, T.rüner M. Clinical impact of cytomegalovirus infection in patients with inflammator bowel disease. Turk J Gastroenterol. 2026;37(3):373-379.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.